



Financial Tear Sheet

Corporate Profile

Incyte's mission is to become one of the leading global oncology companies.

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company's website at www.incyte.com.

Primary IR Contact

Michael Booth, D.Phil.
Vice President, Investor Relations

Phone: 302.498.5914

Fax: 302.425.2707

E-mail: mbooth@incyte.com

Stock Performance

INCY (Common)

| | |
|-------------|-----------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$68.43 |
| Change (%) | ▼ 0.62 (0.90%) |
| Volume | 3,355,104 |
| 52 Week Low | \$61.30 |
| Market Cap | \$14,493,387,710 |
| Rolling EPS | -1.53 |
| PE Ratio | N/A |

Shares Outstanding 211,798,739

Data as of April 20, 2018 4:00 p.m. ET



Recent Headlines

April 13, 2018

[Incyte to Report First Quarter Financial Results](#)

April 06, 2018

[Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® \(pembrolizumab\) in Patients with Unresectable or Metastatic Melanoma](#)

March 15, 2018

[Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018](#)

Events

| Date | Title |
|-----------------------|--|
| 05/01/18 8:00 a.m. ET | Q1 2018 Incyte Corporation Earnings Conference Call |

Data provided by Nasdaq. Minimum 15 minutes delayed.